CAR-T cells in the treatment of neurological autoimmune diseases

Vonberg, Frederick W., Schroeder, Benjamin E., Edwards, Amy, Sun, Bo, Keh, Ryan Y., Ashraghi, Mohammad Reza, Joe, Dorothy, Gorgoraptis, Nikos, Rees, Jeremy, Davies, Nicholas W. S., Finnerty, Gerald, Willis, Mark, Leite, Maria Isabel, Gold, Ralf, Motte, Jeremias, Carr, Aisling S. and Keddie, Stephen 2026. CAR-T cells in the treatment of neurological autoimmune diseases. Practical Neurology 10.1136/pn-2025-004890

Full text not available from this repository.

Abstract

Chimeric antigen receptor T cells (CAR-T cells) have revolutionised cancer treatment by offering personalised therapy of unprecedented efficacy to patients with relapsed B-cell malignancies and myeloma. CAR-T cells are designed selectively to target CD19 or other B-cell antigens with high affinity, leading to a potent immune response and effective killing of malignant B cells. More recently, CAR-T treatment has been shown to be safe and effective in a very limited number of patients with severe, refractory autoimmune conditions such as systemic lupus erythematosus, systemic sclerosis and myositis. This paper describes the early use and feasibility of CAR-T therapies in the treatment of refractory autoimmune neurological diseases.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Medicine
Publisher:	BMJ Publishing Group
ISSN:	1474-7758
Date of Acceptance:	14 December 2025
Last Modified:	12 Jan 2026 14:46
URI:	https://orca.cardiff.ac.uk/id/eprint/183804

Actions (repository staff only)

Edit Item